JP2019503179A5 - - Google Patents

Download PDF

Info

Publication number
JP2019503179A5
JP2019503179A5 JP2018536777A JP2018536777A JP2019503179A5 JP 2019503179 A5 JP2019503179 A5 JP 2019503179A5 JP 2018536777 A JP2018536777 A JP 2018536777A JP 2018536777 A JP2018536777 A JP 2018536777A JP 2019503179 A5 JP2019503179 A5 JP 2019503179A5
Authority
JP
Japan
Prior art keywords
sequence
protein
cells
expression
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018536777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503179A (ja
JP6937309B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/015130 external-priority patent/WO2017132376A1/en
Publication of JP2019503179A publication Critical patent/JP2019503179A/ja
Publication of JP2019503179A5 publication Critical patent/JP2019503179A5/ja
Application granted granted Critical
Publication of JP6937309B2 publication Critical patent/JP6937309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018536777A 2016-01-27 2017-01-26 ハイブリッドプロモーターおよびその使用 Active JP6937309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662388391P 2016-01-27 2016-01-27
US62/388,391 2016-01-27
PCT/US2017/015130 WO2017132376A1 (en) 2016-01-27 2017-01-26 Hybrid promoter and uses thereof

Publications (3)

Publication Number Publication Date
JP2019503179A JP2019503179A (ja) 2019-02-07
JP2019503179A5 true JP2019503179A5 (enExample) 2021-04-22
JP6937309B2 JP6937309B2 (ja) 2021-09-22

Family

ID=58044162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536777A Active JP6937309B2 (ja) 2016-01-27 2017-01-26 ハイブリッドプロモーターおよびその使用

Country Status (5)

Country Link
US (1) US11028410B2 (enExample)
EP (1) EP3408397B1 (enExample)
JP (1) JP6937309B2 (enExample)
ES (1) ES2823173T3 (enExample)
WO (1) WO2017132376A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240035037A1 (en) * 2016-01-27 2024-02-01 Just-Evotec Biologics, Inc. Transposon-based vectors and uses
US11098310B2 (en) * 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
EP3856910B1 (en) * 2018-09-24 2024-11-20 Merck Sharp & Dohme LLC Expression vectors for eukaryotic expression systems
PT115073A (pt) 2018-10-09 2020-05-29 Inst De Biologia Molecular E Celular Ibmc Ácido nucleico para ativar a expressão e a produção de proteínas
US11566262B2 (en) 2021-03-24 2023-01-31 Dna Twopointo Inc. Tetracycline-inducible expression systems
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
EP4711442A1 (en) 2024-09-15 2026-03-18 Quantitative Biosciences, Inc. Microfluidic chip for the parallel culture of microbial biosensor strains

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
AU633020B2 (en) 1988-07-23 1993-01-21 Novozymes Delta Limited New secretory leader sequences
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6022952A (en) 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
EP1132479B1 (en) 1998-11-20 2009-04-22 Fuso Pharmaceutical Industries Ltd. Protein expression vector and utilization thereof
CA2368068A1 (en) 1999-03-18 2000-09-21 Steven M. Ruben 27 human secreted proteins
US20050005310A1 (en) 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
GB2355459B (en) 1999-11-29 2001-09-26 Isis Innovation A dominant conditional lethal genetic system
CA2426100A1 (en) 2000-11-03 2002-05-23 Genentech, Inc. Metabolic rate shifts in fermentations expressing recombinant proteins
CA2504595A1 (en) 2002-11-14 2004-06-03 Lynne Krummen Intron fusion construct and method of using for selecting high-expressing production cell lines
ATE399872T1 (de) 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
UA91818C2 (ru) 2003-08-14 2010-09-10 Уайт Рекомбинантные молекулы лубрицина и их использование
KR20050022071A (ko) 2003-08-26 2005-03-07 삼성에스디아이 주식회사 플라즈마 디스플레이 패널
US20080032300A1 (en) 2004-12-02 2008-02-07 Laboratories Serono S.A. Lupac Bifunctional Marker and Its Use in Protein Production
CA2590284A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
AU2007212540A1 (en) 2006-02-03 2007-08-16 Wyeth Lingo-1 structure
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
EP2046953A4 (en) 2006-08-07 2010-01-27 Synageva Biopharma Corp HYBRID PROMOTERS
FR2910490B1 (fr) 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
KR100884214B1 (ko) 2007-04-04 2009-02-19 주식회사 마크로젠 Ｃａｅｖ-계 벡터 시스템
ATE535607T1 (de) 2007-06-29 2011-12-15 Hoffmann La Roche Promotor
ES2695999T3 (es) 2007-10-12 2019-01-11 Hoffmann La Roche Expresión de proteínas a partir de múltiples ácidos nucleicos
AU2008314697B2 (en) 2007-10-22 2013-08-29 Merck Serono S.A. Single IFN-beta fused to a mutated lgG Fc fragment
KR101603109B1 (ko) 2007-12-07 2016-03-25 지모제넥틱스, 인코포레이티드 Ｉｌ-31에 특이적인 인간화된 항체 분자
US8795981B2 (en) 2008-08-08 2014-08-05 Molecular Devices, Llc Cell detection
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
GB201004143D0 (en) 2010-03-12 2010-04-28 Isis Innovation Promoter sequence for DNA and viral vectors
CA2777978A1 (en) 2011-05-27 2012-11-27 Abbott Biotherapeutics Corp. Dac hyp compositions and methods
WO2013022972A1 (en) 2011-08-08 2013-02-14 Abbott Biotherapeutics Corporation Methods of treating progressive forms of multiple sclerosis
US20140295497A1 (en) 2011-11-30 2014-10-02 Taymar E. Hartman Vectors and host cells comprising a modified sv40 promoter for protein expression
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
RU2756910C2 (ru) 2011-12-22 2021-10-06 Ф. Хоффманн-Ля Рош Аг Комбинации элементов экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
EP2825641A4 (en) 2012-03-12 2015-09-30 Hanwha Chemical Corp EXPRESSION VECTOR WITH A POLYNUCLEOTIDE CODING FOR A MODIFIED GLUTAMINE SYNTHETASE AND METHOD FOR PRODUCING A TARGET PROTEIN THEREFOR
ES2711554T3 (es) 2012-05-22 2019-05-06 Bristol Myers Squibb Co Anticuerpos biespecíficos contra IL-17A/F IL-23 y sus usos
EP2674495A1 (en) 2012-06-14 2013-12-18 Sanofi CHO expression system
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
EP2921554B1 (en) * 2012-10-10 2019-12-04 Chugai Seiyaku Kabushiki Kaisha Method for establishing modified host cell
US9290552B2 (en) 2012-12-21 2016-03-22 Dna Twopointo, Inc. Fluorescent and colored proteins and methods for using them
MY186731A (en) 2013-03-08 2021-08-14 Neuclone Biologics Pty Ltd A cell expression system
WO2015053523A1 (ko) 2013-10-07 2015-04-16 한화케미칼 주식회사 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법
WO2015157579A2 (en) 2014-04-09 2015-10-15 Dna2.0, Inc. Enhanced nucleic acid constructs for eukaryotic gene expression
US10344285B2 (en) 2014-04-09 2019-07-09 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
US12534502B2 (en) 2016-10-04 2026-01-27 Svar Life Science Ab FGF21 responsive reporter gene cell line
US11280790B2 (en) 2016-10-04 2022-03-22 Svar Life Science Ab System and products for improved quantification of ADCC activity

Similar Documents

Publication Publication Date Title
JP6937309B2 (ja) ハイブリッドプロモーターおよびその使用
US10975151B2 (en) ASPGR antibodies and uses thereof
US11685933B2 (en) Inducible expression from transposon-based vectors and uses
US11692193B2 (en) Expression from transposon-based vectors and uses
JP7504027B2 (ja) 互いに連結された２つの抗原結合ドメインを含む抗原結合分子
CN111448314A (zh) 根据可开发性选择真核细胞展示系统中的多肽药物
CN107312796A (zh) 蛋白质的生产方法
KR102559149B1 (ko) 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
JP2018535213A (ja) ＩｇＧ軽鎖におけるＮ末端切断の防止
US20190346456A1 (en) High throughput antibody variant screening method
JP2017530718A (ja) 宿主細胞における異種由来遺伝子の発現を改善するためのプロモーター及び調節エレメント
JP2023179537A (ja) 改変されたヒト可変ドメイン
US20240035037A1 (en) Transposon-based vectors and uses
US20190031752A1 (en) Method for Producing Antibodies
TW202321312A (zh) 包含基於ｍｈｃ或ｍｈｃ樣蛋白的異源二聚體的二價雙特異性嵌合抗體
TW202328184A (zh) 特異性識別fcrn的抗體及其用途
WO2025190332A1 (zh) 特异性结合nkg2a抗原和pd-l1抗原的多特异性抗体及其应用
CN101180316A (zh) 在哺乳动物宿主细胞中高水平表达重组抗体
JP2010536345A (ja) 新規な方法および細胞系
BR112013013354A2 (pt) molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente